It's hard to believe that a week has passed since we were dashing from meeting to meeting in San Francisco. We conducted 29 scheduled meetings at the Biotech Showcase,…
The decks have been prepared, edited, and uploaded to the cloud. The meeting schedule is finalized. The objective of each meeting is clear. Air, hotel, and ground transportation is all…
In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part Two of this series, Dr. Lindemann highlights some of…
Mind The Gap... We're late to this party, but a really good interview of David Grainger from Index Ventures was published in July of this year. We encourage you to read…
The new DiMasi estimates for R&D costs were published this week. You can get a PDF of their slides here, while Ed Silverman has a nice summary in the WSJ. According…
Earlier this week, The Economist travels over well-trod ground in an article on pharmaceutical industry M&A: It used to be all about achieving sheer scale, and building a broad portfolio…
Can't get there from here... We're back from another excellent BIO Europe convention. Held in Frankfurt, this year's version was attended by over 3,000 industry colleagues, experts, investors, and…
There's more to Wyoming than this. In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part…
Is this the next major biotech cluster in the US? Wyoming? Yes, Wyoming. Why not? In the First of a Three-part series, our guest blogger Dr. Garrett Lindemann (@WyomingScience) discusses the…
The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called "inversions" were not…